Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,112.20 -206.04 -1.35%
S&P 500 1,628.93 -22.88 -1.39%
Nasdaq 3,443.20 -38.98 -1.12%
Ticker Volume Price Price Delta
STOXX 50 2,683.98 -16.95 -0.63%
FTSE 100 6,348.82 -25.39 -0.40%
DAX 8,197.08 -32.43 -0.39%
Ticker Volume Price Price Delta
Nikkei 13,245.20 +237.94 1.83%
Hang Seng 20,986.90 -238.99 -1.13%
S&P/ASX 200 4,861.38 +47.03 0.98%
  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

Cynapsus Therapeutics Inc

+ Add to Watchlist

CYNAF:US

0.4153 USD 0.0173 4.35%

As of 20:10:00 ET on 06/14/2013.

Company Profile for Cynapsus Therapeutics Inc (CYNAF)

Cynapsus Therapeutics, Inc. researches and develops pharmaceuticals. The Company researches treatments for Parkinson's disease, neuropathic pain associated with multiple sclerosis and cancer, and nausea and vomiting and appetite stimulation.

Contact Information

Cynapsus Therapeutics Inc

828 Richmond Street West
Toronto, ON M6J 1C9
Canada
Phone: 1-416-703-2449
Fax: 1-416-703-8752

Key Executives for Cynapsus Therapeutics Inc (CYNAF)

Anthony J GiovinazzoPresident/CEOAndrew Michael WilliamsCFO/COO
Nathan BrysonChief Scientific Officer

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil